Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-22
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for breast
cancer with a BRCA mutation.
The interventions involved in this study are:
- Sapacitabine (CYC682)
- Olaparib (Lynparza™)